Treace Medical Concepts Inc. Common Stock (TMCI)
Stock · NASDAQ · Health Care
$3.88as of 10/16/2026
Price chart
Active signals
TMCI Signal Track Record
How signals performed across all stocks →What TMCI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -5.2% | 44% | October 6, 2026 |
| Bollinger Band Breakdown | 25 | -5.1% | 44% | October 6, 2026 |
| Bollinger Band Breakout | 18 | +7.2% | 72% | August 4, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -7.1% | 25% | June 1, 2026 |
| Any 20-session window (baseline) | -1.7% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TMCI
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bun…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 450
- Website
- www.treace.com/
Fundamentals
- 1-day range
- $3.87$4.11
- Market cap
- $284.14M
- P/E (trailing)
- —
- P/E (forward)
- -4.55
- EPS (trailing)
- $-0.93
- Dividend yield
- —
- Beta
- 1.57
- Avg. volume
- 301.8K
How Treace Medical Concepts Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Feb 27, 2025 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Treace Medical Concepts Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TMCITreace Medical Concepts Inc. Common Stock$3.87▼ 6.07%Market cap $284.14MP/E —$1.17$7.08
- DRTSWAlpha Tau Medical Ltd. Warrant$2.68▼ 10.37%Market cap $284.27MP/E —$0.2725$4.62
- PROFProfound Medical Corp. Common Stock$6.01▼ 4.75%Market cap $288.52MP/E —$6.52$12.4
- OSUROraSure Technologies Inc. Common Stock$3.61▼ 5.25%Market cap $275.39MP/E —$2.08$4.58
- ANIKAnika Therapeutics Inc. Common Stock$19.98▼ 3.43%Market cap $269.80MP/E —$8.67$22.88
- INFUInfuSystems Holdings Inc. Common Stock$13.4▼ 3.74%Market cap $236.42MP/E 31.71$7.29$13.85
- SENSSenseonics Holdings Inc. Common Stock$7.77▼ 5.59%Market cap $215.29MP/E —$4.79$10.64
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TMCI Treace Medical Concepts Inc. Common Stock | $284.14M | — | $3.87 | ▼ 6.07% | $1.17$7.08 |
| DRTSW Alpha Tau Medical Ltd. Warrant | $284.27M | — | $2.68 | ▼ 10.37% | $0.2725$4.62 |
| PROF Profound Medical Corp. Common Stock | $288.52M | — | $6.01 | ▼ 4.75% | $6.52$12.4 |
| OSUR OraSure Technologies Inc. Common Stock | $275.39M | — | $3.61 | ▼ 5.25% | $2.08$4.58 |
| ANIK Anika Therapeutics Inc. Common Stock | $269.80M | — | $19.98 | ▼ 3.43% | $8.67$22.88 |
| INFU InfuSystems Holdings Inc. Common Stock | $236.42M | 31.71 | $13.4 | ▼ 3.74% | $7.29$13.85 |
| SENS Senseonics Holdings Inc. Common Stock | $215.29M | — | $7.77 | ▼ 5.59% | $4.79$10.64 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga · 10/7/2026
- Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?Yahoo · 9/23/2026
- Treace Medical Looks Unlikely To Recover, A Founder-Led Broken Growth StorySeekingAlpha · 9/20/2026
- Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® ProcedureYahoo · 9/17/2026
- Treace Medical Presents 5-Year ALIGN3D Data Showing 0.8% Recurrence Rate Alongside MTA3D And SPRINT Clinical Results At AOFAS 2026Benzinga · 9/17/2026
- Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?Yahoo · 9/17/2026
- Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual MeetingYahoo · 9/15/2026
Insider Activity
Insider Actions →- Elder Scot Michael · September 30, 2026 · Tax Withholding25.5K
- Treace John T. · August 24, 2026 · Buy11.0K @ $4.34
- Treace John T. · August 21, 2026 · Buy5.0K @ $4.35
- Treace John T. · August 20, 2026 · Buy39.9K @ $4.44
- Scanlan Sean F. · August 9, 2026 · Tax Withholding9.8K
- Hair Mark · August 9, 2026 · Tax Withholding37.1K
- Elder Scot Michael · August 9, 2026 · Tax Withholding16.3K
- Treace John T. · June 11, 2026 · Buy22.9K @ $4.04
- Treace John T. · June 11, 2026 · Buy9.9K @ $4.04
- Treace John T. · June 10, 2026 · Buy14.7K @ $4.02
- Treace John T. · June 10, 2026 · Buy29.4K @ $4.02
- Treace John T. · June 1, 2026 · Buy50.0K @ $3.56
- Treace John T. · May 28, 2026 · Buy61.2K @ $3.02
- Treace John T. · May 27, 2026 · Buy49.8K @ $2.87
- Treace John T. · May 26, 2026 · Buy4.5K @ $2.79
Institutional Ownership
March 31, 2026
- Total shares held
- 35.19M
- Total value held
- $45.42M
- Institutional holders
- 113
- Unknown6.36M
- Unknown5.20M
- Unknown3.34M
- Unknown3.21M
- Unknown1.46M
- Unknown1.24M
- Unknown1.22M
- Unknown1.15M
- Unknown1.06M
- Unknown1.01M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Treace Medical Shares Five-Year Bunion Study Results
Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.
Treace Medical Shares Five-Year Bunion Study Results. Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.